- Home
- MYPS vs ZNTL Comparison
MYPS vs ZNTL Comparison
Compare MYPS & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYPS
- ZNTL
- Stock Information
- Founded
- MYPS 2011
- ZNTL 2014
- Country
- MYPS United States
- ZNTL United States
- Employees
- MYPS N/A
- ZNTL N/A
- Industry
- MYPS EDP Services
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- MYPS Technology
- ZNTL Health Care
- Exchange
- MYPS Nasdaq
- ZNTL Nasdaq
- Market Cap
- MYPS 121.6M
- ZNTL 105.8M
- IPO Year
- MYPS N/A
- ZNTL 2020
- Fundamental
- Price
- MYPS $0.97
- ZNTL $1.63
- Analyst Decision
- MYPS Buy
- ZNTL Buy
- Analyst Count
- MYPS 5
- ZNTL 7
- Target Price
- MYPS $2.50
- ZNTL $8.46
- AVG Volume (30 Days)
- MYPS 248.3K
- ZNTL 828.3K
- Earning Date
- MYPS 11-03-2025
- ZNTL 08-06-2025
- Dividend Yield
- MYPS N/A
- ZNTL N/A
- EPS Growth
- MYPS N/A
- ZNTL N/A
- EPS
- MYPS N/A
- ZNTL N/A
- Revenue
- MYPS $261,058,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- MYPS N/A
- ZNTL N/A
- Revenue Next Year
- MYPS N/A
- ZNTL N/A
- P/E Ratio
- MYPS N/A
- ZNTL N/A
- Revenue Growth
- MYPS N/A
- ZNTL N/A
- 52 Week Low
- MYPS $0.90
- ZNTL $1.01
- 52 Week High
- MYPS $2.29
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- MYPS 39.84
- ZNTL 49.52
- Support Level
- MYPS $0.94
- ZNTL $1.60
- Resistance Level
- MYPS $0.98
- ZNTL $2.02
- Average True Range (ATR)
- MYPS 0.04
- ZNTL 0.16
- MACD
- MYPS 0.01
- ZNTL -0.02
- Stochastic Oscillator
- MYPS 43.00
- ZNTL 16.00
About MYPS PLAYSTUDIOS Inc.
PLAYSTUDIOS Inc is engaged in gaming and related business. The Company develops and operates online and mobile social gaming applications (games or game), many of which incorporate a loyalty program offering real world rewards provided by a collection of awards partners. The Company's games are free-to-play and available via the Apple App Store, Google Play Store, Amazon Appstore and Facebook (collectively, platforms or platform operators). The Company creates games based on its own original content as well as third-party licensed brands. The Company generates revenue through the in-game sales of virtual currency and through advertising. The company has one operating segment with one business activity, developing and monetizing social games.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.